Clinical trial
Prevention of Recurrent Hepatitis B After Liver Transplantation
NCT00059267 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00059267 |
|---|---|
| Title | Prevention of Recurrent Hepatitis B After Liver Transplantation |
| Official title | Prevention of Recurrent Hepatitis B After Liver Transplantation |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | University of Michigan |
| Status | Completed |
| Study type | Observational |
| Conditions | Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | HBIG, Epivir, Hepsera |
| Enrollment | 317 |
| Start date | Mar 1, 2001 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 23, 2003 |
| Last update posted | Nov 15, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: